Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhen Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4134-1779; OpenAlex author ID A5100422432. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Co-author DOI 10.1038/s41419-025-07495-2↗
  2. Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: FCGR3A as key gene. Co-author DOI 10.32604/or.2024.055286↗
  3. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway. First author DOI 10.1016/j.pan.2022.03.002↗
  4. MicroRNA-1469-5p promotes the invasion and proliferation of pancreatic cancer cells via direct regulating the NDRG1/NF-κB/E-cadherin axis. Co-author DOI 10.1007/s13577-020-00399-7↗
  5. Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Co-author DOI 10.1038/s41419-018-0574-1↗
  6. Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway. First author DOI 10.7150/jca.18628↗
  7. Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2016.03.099↗
  8. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Co-author DOI 10.18632/oncotarget.3885↗
  9. Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. First author DOI 10.3892/or.2014.3158↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Liang · 3 shared papers, 2015–2025 · strength 0.37
  2. Hong‐Xi Xu · 2 shared papers, 2018–2025 · strength 0.32
  3. Yang Li · 2 shared papers, 2018–2025 · strength 0.32
  4. Ying-Yi Li · 2 shared papers, 2018–2025 · strength 0.32
  5. Dunfeng Qi · 1 shared paper, 2024 · strength 0.22
  6. Meng Wang · 1 shared paper, 2024 · strength 0.22
  7. Jinlan Shan · 1 shared paper, 2022 · strength 0.16
  8. Tao Zhang · 1 shared paper, 2022 · strength 0.16
  9. Xiyong Liu · 1 shared paper, 2022 · strength 0.16
  10. Xiaochen Wang · 1 shared paper, 2022 · strength 0.16
  11. Changru Fan · 1 shared paper, 2020 · strength 0.13
  12. Jinju Liu · 1 shared paper, 2020 · strength 0.13
  13. Ying-Yi Li · 2 shared papers, 2015–2016 · strength 0.12
  14. Ting Li · 1 shared paper, 2017 · strength 0.10
  15. Yingyi Li · 1 shared paper, 2017 · strength 0.10
  16. Hongyu Li · 2 shared papers, 2014–2015 · strength 0.10
  17. Xiang-Yuan Chen · 1 shared paper, 2016 · strength 0.08
  18. Bin Liu · 1 shared paper, 2014 · strength 0.05
  19. Yingyi Li · 1 shared paper, 2014 · strength 0.05
  20. Naofumi Mukaida · 1 shared paper, 2015 · strength 0.05
  21. Yao Hua Song · 1 shared paper, 2015 · strength 0.05
  22. Xianjun Yu · 1 shared paper, 2015 · strength 0.05
  23. Xiaozhong Guo · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.